Hypoxia imaging with [F-18] FMISO-PET in head and neck squamous cell carcinoma

Tumor hypoxia adversely affects clinical radiation response of head and neck squamous cell carcinoma. 18F-fluoromisonidazole positron emission tomography ([F-18]FMISO-PET) offers a noninvasive means of assessing viable hypoxic tissue in tumor. We evaluate hypoxia imaging with [F-18]FMISO-PET in HNSCC treated with chemoradiotherapy. A total of 11 patients with HNSCC agreed to participate in this study. All of the patients underwent pretreatment [F-18]FMISO-PET. SUVmax and tumor-to-muscle ratios(TMR) were measured as hypoxia indicators. 9 patients of them had primary tumor hypoxia. 2 of 10 patients with neck metastasis had nodal hypoxia. All patients were treated with chemoradiation therapy. As clinical response of chemoradiotherapy, 8 patients achieved CR, 3 patients achieved PR. Remain viable carcinoma cell of 3 PR cases existed in hypoxia region imaged with [F-18]FMISO-PET. The current result suggest that we could apply 18-F fluoromisonidazole positron emission tomography/computed tomography ([F-18]FMISO-PET/CT)-guided intensity-modulated radiotherapy(IMRT) in dose escalation to attack the hypoxic volume of a tumor mass without increasing the normal tissue dose in head and neck cancer patients in order to improve the clinical response.

Only gold members can continue reading. Log In or Register to continue

Jan 21, 2018 | Posted by in Oral and Maxillofacial Surgery | Comments Off on Hypoxia imaging with [F-18] FMISO-PET in head and neck squamous cell carcinoma
Premium Wordpress Themes by UFO Themes